Solamargine + Solasonine

A cream formulation containing a synergistic mixture of the glycoalkaloids Solamargine + Solasonine purified from the plant species Solanum sodomaeum (Curaderm) is effective in the treatment of the malignant human skin tumours; basal cell carcinomas (BCCs), squamous cell carcinomas (SCCs) and the benign tumours; keratoses and keratoacanthomas.

Analyses of biopsies taken before, during and after treatment give compelling evidence of the efficacy of the formulation. The treated lesions did not recur for at least 3 years after cessation of therapy.

Biochemical, haematological and urinanalytical studies demonstrated that there were no adverse effects on the liver, kidneys or haematopoietic system during treatment. Normal skin treated with the formulation likewise was free from adverse histological or clinical effects.

The data indicate that glycoalkaloids of this type are therefore potentially useful in the treatment of several types of human skin cancers.

Glycomix can offer a highly purified (>98%) product suitable as development material for research into the therapeutic properties of this synergistic mixture. The product has been purified according to USP 7,497,290 (Jan 20th 2009)-“Solvent Extraction Process” and is available in evaluation quantities.